Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)

Completed

Conditions studied: Age-related Macular Degeneration (AMD)

In brief

This study was a retrospective cohort study of patients to assess the early insights into real-world safety among wet AMD patients initiating brolucizumab. Evidence was generated to describe their patient characteristics and clinical outcomes. The study was conducted using the IRIS Registry.

Key facts

Study ID

NCT05082415

Run by

Novartis Pharmaceuticals

People needed

9456

Starts

2020-06-03

Expected to finish

2020-12-15

Last updated by the study team

2021-10-27

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ≥1 Healthcare Common Procedure Coding System (HCPCS) code (J code) or EMR note for treatment with brolucizumab during the index period (date of earliest code or EMR note = index date)
• ≥18 years old on the index date
• ≥1 Current Procedural Terminology (CPT) code for intravitreal administration on the index date
• ≥1 International Classification of Diseases, Clinical Modification-9/10 (ICD-9/10) code for wet AMD in the 36 months prior to or on the index date
• o Note: Off-label use of brolucizumab is not expected given payer access restrictions in the US.
• ≥1 follow-up visit after the index date
• ≥1 VA assessment on the index date or within 90 days prior to the index date

You may not qualify if…

• Use of brolucizumab prior to 10/8/2019 (e.g. clinical trials)
• Unknown laterality of the index eye on the index date

Where it is running

• Novartis Pharmaceuticals — East Hanover, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.